// App-Quantinova.ai

: Serum KL-6 as a marker of disease progression in SSc-ILD

Researchers

Presenter

  • Carmel Stock

Principal Investigators

  • Rachel Hoyles

  • Cecile D'Accord

  • Maria Kokosi

  • Veronica Alfieri

  • Corrado Campochiaro

  • Jackie Donovan

  • Letizia Mori

  • Toby M Maher

  • Vasilis Kouranos

  • George Margaritopoulos

  • Peter M George

  • Philip L Molyneaux

  • Felix Chua

  • Voon Ong

  • Christopher P Denton

  • Athol U Wells

  • Elizabetta A Renzoni

Medical Centers

  • Imperial College, Royal Brompton Hospital, London, United Kingdom

  • University College London School of Medicine, Royal Free Hospital, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • Kerbs von Lungren 6 antigen

  • Cancer antigen 15-3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved